KalVista Pharmaceuticals, Inc.
DE ˙ DB ˙ US4834971032
23,01 € 0,00 (0,00%)
2026-06-04
DEL PRIS
SecurityDE:4XC1 / KalVista Pharmaceuticals, Inc.
InstitutionQube Research & Technologies Ltd
Latest Disclosed Ownership180,314 shares
Latest Disclosed Value $ 3,629,721
Qube Research & Technologies Ltd ownership in 4XC1 / KalVista Pharmaceuticals, Inc.

On May 15, 2026 - Qube Research & Technologies Ltd filed a 13F-HR form disclosing ownership of 180,314 shares of KalVista Pharmaceuticals, Inc. (DE:4XC1) valued at $2,794,867 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 0 shares of KalVista Pharmaceuticals, Inc.. The current value of the position is $4,149,025 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 180,314 180,314 3,630 0.0040
2026-02-17 2025-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 0 -325,435 -100.00 0 -100.00
2025-11-14 2025-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 325,435 228,187 234.64 3,964 260.60 0.0041
2025-08-14 2025-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 97,248 97,248 1,099 0.0011
2025-05-15 2025-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 0 -126,132 -100.00 0 -100.00
2025-02-14 2024-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 126,132 -52,476 -29.38 1,068 -48.36 0.0014
2024-11-14 2024-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 178,608 149,019 503.63 2,068 494.25 0.0030
2024-08-14 2024-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 29,589 -149,149 -83.45 349 -83.58 0.0006
2024-05-14 2024-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 178,738 178,738 2,120 0.0034
2021-08-13 2021-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 0 -21,030 -100.00 0 -100.00
2021-05-14 2021-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 21,030 21,030 540 0.0086
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.